VALN Valneva SE IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1836564 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 | 2024Q3*2024-09-30 | 2024Q2*2024-06-30 | 2024Q1*2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 47.69M | 29.41M | 48.33M | 49.23M | 52.94M | 45.82M | 38.06M | 32.75M |
| Cost of revenue | 36.07M | 23.91M | 24.12M | 23.04M | 27.23M | 25.68M | 23.47M | 22.16M |
| Gross profit | 11.62M | 5.50M | 24.21M | 26.19M | 25.71M | 20.15M | 14.59M | 10.59M |
| R&D expense | 25.57M | 27.29M | 17.49M | 14.95M | 25.58M | 18.88M | 16.55M | 13.13M |
| SG&A expense | 7.80M | 10.49M | 10.07M | 8.96M | 10.20M | 9.71M | 11.18M | 11.67M |
| Operating income | -28.11M | -37.12M | -10.87M | -5.96M | -20.88M | -12.45M | -21.55M | 68.21M |
| Interest expense | 24.64M | 5.67M | 5.61M | 5.98M | 6.27M | 5.73M | 4.94M | 7.04M |
| Pretax income | -51.08M | -43.47M | -11.81M | -7.76M | -32.35M | -12.96M | -25.10M | 58.92M |
| Income tax | -1.06M | 882,000 | -223,000 | 1.47M | 4.64M | -3.72M | -166,000 | 8,000 |
| Net income | -50.02M | -44.35M | -11.59M | -9.23M | -36.99M | -9.24M | -24.93M | 58.91M |
| EPS (basic) | — | — | — | -0.06 | — | — | — | 0.42 |
| EPS (diluted) | — | — | — | -0.06 | — | — | — | 0.41 |
| Balance sheet | ||||||||
| Cash & equivalents | 109.65M | 143.46M | 161.31M | 152.99M | 168.27M | 156.34M | 131.41M | 176.64M |
| Receivables | 27.81M | 20.08M | 24.12M | 33.52M | 35.20M | 30.36M | 30.52M | 27.29M |
| Inventory | 50.23M | 64.29M | 61.73M | 61.68M | 53.66M | 57.83M | 48.87M | 48.59M |
| Current assets | 222.54M | 268.33M | 284.72M | 287.05M | 299.01M | 303.61M | 269.15M | 306.24M |
| PP&E, netmay include right-of-use assets (IFRS) | 119.47M | 123.40M | 128.47M | 134.38M | 138.88M | 141.65M | 137.45M | 136.70M |
| Intangibles | 22.35M | 23.07M | 23.82M | 24.60M | 25.26M | 33.48M | 24.19M | 24.85M |
| Total assets | 398.84M | 448.23M | 472.62M | 482.24M | 500.03M | 516.61M | 466.57M | 502.83M |
| Current liabilities | 93.33M | 150.48M | 125.66M | 106.20M | 114.58M | 109.16M | 102.49M | 116.08M |
| Short-term debt | 17.91M | 58.83M | 46.02M | 19.70M | 20.85M | 19.45M | 19.87M | 22.41M |
| Long-term debt | 161.26M | 108.89M | 122.36M | 161.48M | 166.52M | 153.13M | 160.55M | 159.03M |
| Total debt | 179.17M | 167.72M | 168.38M | 181.18M | 187.37M | 172.58M | 180.42M | 181.45M |
| Total liabilities | 292.67M | 297.75M | 286.19M | 306.99M | 318.78M | 299.14M | 300.29M | 313.60M |
| Shareholders' equity | 106.17M | 150.48M | 186.43M | 175.25M | 181.25M | 217.47M | 166.28M | 189.23M |
| Net debt | 69.52M | 24.26M | 7.08M | 28.19M | 19.10M | 16.24M | 49.00M | 4.81M |
| Shares outstanding | 173.42M | — | — | — | 162.40M | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -24.51M | -17.44M | -2.79M | -8.15M | 9.53M | -10.48M | -37.83M | -28.43M |
| Capital expenditure | 1.08M | 668,000 | 1.26M | 1.40M | 3.86M | 5.90M | -394,000 | 4.50M |
| Free cash flow | -25.59M | -18.11M | -4.06M | -9.55M | 5.67M | -16.39M | -37.44M | -32.93M |
| Investing cash flow | -264,000 | 197,000 | -681,000 | -961,000 | 4.69M | -15.38M | 895,000 | 86.71M |
| Financing cash flow | -9.36M | -556,000 | 14.88M | -5.58M | -4.59M | 51.86M | -9.13M | -7.46M |
Free plan shows the latest 8 periods; Pro shows all 20 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.